We enable your product’s success by translating medical research into outstanding biopharmaceuticals.

Scroll down

Best-in-class regulatory compliance

Best-in-class regulatory compliance

All-in-one service experience

All-in-one service experience

Complex/designer molecule competency

Complex protein competency

Scientific  Excellence

Scientific Excellence across all functions

Customized  solution

Unparalleled client centricity

Unparalleled customer centricity

Fully tailored end-to-end solutions

About Rentschler Biopharma

Rentschler Biopharma is a leading global contract development and manufacturing organization (CDMO) with almost 50 years of proven scientific expertise in biotechnology. From our headquarters in Laupheim, Germany, and our site in Milford, MA, USA, we are your outsourcing partner for bioprocess development and cGMP manufacturing. Our exceptional track record with over 110 different therapeutic protein formats and client-oriented consulting activities, including project management and regulatory support, ensure your project’s success.

We acquired our U.S. site in Milford, MA, in the greater Boston area, in January 2019. The FDA, EMA and Health Canada-licensed, 93,000 square foot facility will be qualified as a multi-product site offering clients innovative solutions. We are expanding the site into a center of excellence, with multiple technologies and capabilities for a variety of products. The first step in the expansion was a 500 L single-use bioreactor, which is already operational. We have broken ground at our new production site, adjacent to our existing site in Milford, MA. The new Rentschler Biopharma Manufacturing Center US (RBMC US) will add 22,000 square feet of manufacturing cleanroom space and house four new 2,000 L single-use bioreactors. With an innovative and highly flexible business model, we are already taking on new projects in Milford, including complex and difficult-to-manufacture proteins.

More

Rentschler Biopharma offers bioprocess development and cGMP manufacturing for high-quality biopharmaceuticals. Our strength lies in our extensive experience with complex proteins. We provide the best solutions to guarantee the success of your project and meet your clinical and commercial needs.

More

Why partner with Rentschler Biopharma?

As a leading global CDMO, our attention is firmly focused on your needs. Our strength lies in our experience with highly complex molecules. Fusion proteins, recombinant enzymes, monoclonal and multi-specific antibodies are among the 110 different formats that we have handled. Our track record of 300 molecules for 150 clients worldwide translates into unrivalled experience along the entire biopharmaceutical value chain. We guarantee best-fit solutions for your product by balancing timeline requirements with a comprehensive manufacturability assessment, always putting quality first.

 

More

Team Rentschler Biopharma

Empowering our partners - every step of the way

We are dedicated to providing solutions for your most complex challenges and speed for your standard tasks. Your first point of contact is our business development team, who will support you in finding solutions tailored to your needs. Our exceptional team of scientific experts, our client-oriented project management and our strong experience in regulatory affairs support will ensure the success of your project.

Get in touch

Upcoming Events

Bio Convention

Swiss Biotech Day

Virtual

BPI Boston

Hybrid (Boston, MA, USA and Virtual)

Deutsche Biotechnologietage

Stuttgart

BioTalk EU

Virtual

 BioJapan

Pacifico Yokohama

BioTalk US

Virtual

BioEurope Digital

Virtual

News

Rentschler Biopharma donates 50,000 Euros to support construction of the Albert Einstein Discovery Center in Ulm

Rentschler Biopharma appoints Dr. Christian Schetter as Chief Scientific Officer, strengthening scientific focus

Rentschler Biopharma breaks ground at new U.S. production site in greater Boston

Rentschler Biopharma´s Insights

A vision for achieving worldwide biopharmaceutical CDMO leadership

CEO Frank Mathias’ article on Strategy 2025

Download

Rentschler Biopharma expands U.S. footprint

Interview by our SVP Business Development Federico Pollano

Download

Outsourcing services from gene to patient

CEO Frank Mathias in CHEManager

Download